盘龙药业签约战略合作，深耕大健康领域，助推“一体两翼”发展战略

Group 1 - The strategic cooperation between Shaohua Health and Panlong Pharmaceutical aims to enhance the development of the health industry through joint research, production, sales, and services of health products [1] - Panlong Pharmaceutical focuses on developing unique health products based on the Qinling region, collaborating with universities to create exclusive products [1] - The health industry in China is rapidly growing, with a market size of 14.48 trillion yuan in 2023, projected to reach 17.4 trillion yuan by 2025 and 29.1 trillion yuan by 2030 [2] Group 2 - Panlong Pharmaceutical's "One Body, Two Wings" strategy focuses on industrial development, commercial distribution, and traditional medicine heritage to achieve high-quality growth [3] - The company has reported continuous growth in revenue and net profit for seven consecutive years, with a net profit increase of 6.5% year-on-year in the latest quarterly report [3] - The compound annual growth rates for revenue and net profit over the past seven years are 18.14% and 15.81%, respectively, placing the company among the top five in the Chinese herbal medicine sector with a market cap below 5 billion yuan [3]